GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
- GRI Bio's unique approach to targeting NKT cells earlier in the inflammatory cascade has the potential to provide more effective treatment options for idiopathic pulmonary fibrosis (IPF) and lupus.
- The market for IPF treatments is already a multi-billion dollar market worth $3.9 billion in 2022.
- None.
LA JOLLA, CA / ACCESSWIRE / August 25, 2023 / Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that are more widely known are Idiopathic Pulmonary Fibrosis (IPF) and Lupus.
IPF is a chronic lung disease primarily affecting older adults, and the underlying cause is unclear. The lung tissue becomes stiff and scarred over time, making it difficult for oxygen to enter the bloodstream. Sadly, there is no known cure for IPF, and the available treatment options are limited. The disease is often challenging to diagnose, leading to delayed treatment initiation and worsening symptoms. With a median life expectancy of 2-3 years from diagnosis, there is a significant need for more effective therapies, and the market for its treatments is already a multi-billion dollar market worth
Lupus, or Systemic Lupus Erythematosus (SLE), is a chronic autoimmune disease that can affect multiple organs and systems in the body - patients' immune system mistakenly attacks healthy tissues, leading to inflammation and damage. Lupus can manifest differently in each individual, making diagnosis and treatment complex for the rare disease that is nine times more likely to affect women. Existing treatments for Lupus often focus on controlling inflammation and suppressing the immune system. However, these therapies can have significant side effects and may not be effective for all patients. The variability in Lupus manifestations and the lack of tailored treatments contribute to the unmet need for more targeted therapies, which can improve long-term outcomes and quality of life.
Solutions On The Horizon?
Researchers and healthcare providers are actively working towards developing better treatments and interventions to alleviate symptoms, slow disease progression and ultimately improve the lives of those affected by these chronic diseases. GRI Bio (NASDAQ:GRI) is one of these companies. The company is a clinical-stage biopharmaceutical company that is dedicated to revolutionizing the way that inflammatory, fibrotic and autoimmune diseases are treated. The company's mission is to develop life-changing therapies that interrupt disease progression and restore the immune system to its normal state of balance.
GRI Bio's unique approach centers around NKT cells, which are key regulators earlier in the inflammatory cascade. These cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Specifically, the type I invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response and fibrosis observed in inflammatory and fibrotic indications. GRI Bio is focused on developing therapies that inhibit iNKT cell activity to target earlier in the inflammatory cascade to interrupt disease progression and restore homeostasis in the immune system.
The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a serious disease with significant unmet needs, and GRI Bio's unique approach to target NKT cells has the potential to provide a more effective treatment option. Additionally, the company is developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus (SLE).
While companies like Amgen, Bristol Myers Squibb and AstraZeneca are researching these diseases, GRI Bio's unique approach targets NKT cells earlier in the inflammatory cascade - setting it apart from the crowd. With additional clinical stage assets ready for development upon additional funding of partnership, GRI Bio has the potential to make a significant impact in the field of biopharmaceuticals and improve the lives of patients worldwide. Additionally, a library of over 500 proprietary compounds highlights the company's future ability to fuel a growing pipeline and potentially develop new therapies for other inflammatory, fibrotic and autoimmune diseases.
Featured photo by National Cancer Institute on Unsplash.
Contact:
Jenene Thomas
jenene@jtcir.com
SOURCE: GRI Bio, Inc.
View source version on accesswire.com:
https://www.accesswire.com/777127/GRI-Bio-Is-Bringing-Hope-To-Patients-With-Idiopathic-Pulmonary-Fibrosis-And-Lupus
